CTLA-4: new insights into its biological function and use in tumor immunotherapy

By J. Egen, M. Kuhns, James P. Allison. Nature Immunology, 2002

988 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/8f4af4cf909379c88fc65442c7368dbea481b421

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

In Oncology

Citations in the corpus

Regulatory T cells in tumor immunity (2010, background): “CTLA-4 is a negative immunomodulator expressed on activated T cells and delivers an inhibitory signal during immune responses.(90) CTLA-4 is also constitutively expressed by CD25þCD4þTregs and is upregulated after TCR stimulation.”
CD28 and CTLA-4 coreceptor expression and signal transduction (2009, background): “In this context, anti-CTLA-4 coligation can inhibit both TCR and TCR ⁄CD28 activation of cells (153).”
CTLA-4 and PD-1 Pathways (2016, background): “Proposed mechanisms for such inhibitory signals include direct inhibition at the TCR immune synapse, inhibition of CD28 or its signaling pathway, or increased mobility of T cells leading to decreased ability to interact with APCs.(9,12,13) CTLA-4 itself is subject to regulation, particularly by loca”
T-cell-antigen recognition and the immunological synapse (2003, background): “cgi?l=5781">SHP2 (SRC homology 2 (SH2)-domain-containing protein tyrosine phosphatase 2), which dephosphorylates activated CD3 subunit”
Interleukin 27 negatively regulates the development of interleukin 17–producing T helper cells during chronic inflammation of the central nervous system (2006, methodology): “First, we treated infected mice with CTLA-4–Ig, an antagonist of CD28-dependent costimulation of T cell”
Immune infiltration in human tumors: a prognostic factor that should not be ignored (2010, background): “, 2008), and T-cell-specific co-inhibitory molecules (CTLA-4 and PD-1) (Egen et al., 2002; Okazaki and Honjo, 2006).”
PD-1 signaling in primary T cells (2009, background): “We and many others have shown that the main targets of negative regulators of T-cell activation are cell growth and metabolism (13, 15, 39, 83).”